Management reiterated that their De Novo DrugSorb-ATR submission continued to be in interactive review with FDA, that their Medical Device License application to Health Canada was in advanced review, ...
Good afternoon, ladies and gentleman and welcome to the CytoSorbents' Corporation Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlight Conference Call. AT his time all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results